Checkpoint inhibitors targeting the programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) expression in EAOC are promising, as endometriosis-associated ovarian cancer expresses higher levels of PD-1/PD-L1 compared to benign lesions [198]. The gene discussed is PDCD1; the disease is ovarian carcinoma.